Home World News Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with... World News Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with Gastric, GEJ and Oesophageal Adenocarcinoma By Ogkologos - February 24, 2026 388 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 5 years of follow-up of CheckMate 649 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Luspatercept Improves the Rate of RBC Transfusion Independence Compared with Epoetin... June 19, 2023 KRASG12D-Mutated NSCLC is Subtype with Distinct Co-mutations, a Colder Immune Microenvironment,... August 3, 2022 Atezolizumab Approved for Initial Treatment of Metastatic Lung Cancer January 7, 2019 Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer May 21, 2024 Load more HOT NEWS Helping Cancer Survivors Cope with Cancer-Related Anxiety and Distress Trastuzumab Deruxtecan Shows Durable Anticancer Activity in Patients with Previously Treated... ESMO Breast Cancer Virtual Congress 2021, 5-8 May EMA Recommends Granting a Conditional Marketing Authorisation for Talquetamab
